CN111803648A - Traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and preparation method and application thereof Download PDFInfo
- Publication number
- CN111803648A CN111803648A CN202010842875.1A CN202010842875A CN111803648A CN 111803648 A CN111803648 A CN 111803648A CN 202010842875 A CN202010842875 A CN 202010842875A CN 111803648 A CN111803648 A CN 111803648A
- Authority
- CN
- China
- Prior art keywords
- parts
- cockroach
- traditional chinese
- chinese medicine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 106
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 31
- 241000222341 Polyporaceae Species 0.000 claims abstract description 30
- 241000196324 Embryophyta Species 0.000 claims abstract description 28
- 241000208838 Asteraceae Species 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000000575 pesticide Substances 0.000 claims abstract description 9
- 241001674044 Blattodea Species 0.000 claims description 57
- 241000238631 Hexapoda Species 0.000 claims description 32
- 210000002700 urine Anatomy 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 23
- 241000222355 Trametes versicolor Species 0.000 claims description 20
- 241000245665 Taraxacum Species 0.000 claims description 19
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 19
- 210000003608 fece Anatomy 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 244000197580 Poria cocos Species 0.000 claims description 14
- 235000008599 Poria cocos Nutrition 0.000 claims description 14
- 235000001405 Artemisia annua Nutrition 0.000 claims description 12
- 240000000011 Artemisia annua Species 0.000 claims description 12
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 11
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 11
- 235000003130 Arctium lappa Nutrition 0.000 claims description 10
- 235000008078 Arctium minus Nutrition 0.000 claims description 10
- 241000132012 Atractylodes Species 0.000 claims description 10
- 244000020518 Carthamus tinctorius Species 0.000 claims description 10
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 10
- 240000001080 Grifola frondosa Species 0.000 claims description 10
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 10
- 241000222640 Polyporus Species 0.000 claims description 10
- 240000003705 Senecio vulgaris Species 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 241000208843 Arctium Species 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 8
- 241000254173 Coleoptera Species 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 241000222336 Ganoderma Species 0.000 claims description 6
- 241000222684 Grifola Species 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 241000257303 Hymenoptera Species 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 230000009194 climbing Effects 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 206010006326 Breath odour Diseases 0.000 claims description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 3
- 208000032139 Halitosis Diseases 0.000 claims description 3
- 206010013781 dry mouth Diseases 0.000 claims description 3
- 235000008384 feverfew Nutrition 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 241000256844 Apis mellifera Species 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 238000005238 degreasing Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000723353 Chrysanthemum Species 0.000 claims 4
- 241000255626 Tabanus <genus> Species 0.000 claims 1
- 241000238565 lobster Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 206010061218 Inflammation Diseases 0.000 abstract description 16
- 210000004400 mucous membrane Anatomy 0.000 abstract description 16
- 230000004054 inflammatory process Effects 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 12
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 238000005469 granulation Methods 0.000 abstract description 5
- 230000003179 granulation Effects 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 5
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 230000001174 ascending effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 131
- 210000001072 colon Anatomy 0.000 description 55
- 230000002829 reductive effect Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 210000000436 anus Anatomy 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000002550 fecal effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 238000000465 moulding Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102000003896 Myeloperoxidases Human genes 0.000 description 7
- 108090000235 Myeloperoxidases Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 102000004890 Interleukin-8 Human genes 0.000 description 6
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 210000004347 intestinal mucosa Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 239000007963 capsule composition Substances 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000006996 mental state Effects 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000027503 bloody stool Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000000713 mesentery Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 244000171085 Polyporus umbellatus Species 0.000 description 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 101000942127 Rattus norvegicus C-reactive protein Proteins 0.000 description 1
- 101000940868 Rattus norvegicus Cysteine and glycine-rich protein 1 Proteins 0.000 description 1
- 101000998143 Rattus norvegicus Interleukin-17A Proteins 0.000 description 1
- 101001043830 Rattus norvegicus Interleukin-2 Proteins 0.000 description 1
- 101001076459 Rattus norvegicus Interleukin-6 Proteins 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of modern Chinese medicinal preparations, in particular to a Chinese medicinal composition for preventing and treating damp-heat diarrhea and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 10-60 parts of pesticide, 25-55 parts of compositae plants and 15-65 parts of polyporaceae plants. Wherein the Polyporaceae plant has effects of invigorating qi and spleen, the Compositae plant has effects of clearing heat and detoxicating, subsiding swelling and resolving hard mass, and resisting inflammation, and the entomodrug has effects of promoting blood circulation and dredging collaterals, healing sore and promoting granulation, and repairing mucous membrane. The three medicines are combined to achieve the effects of keeping mild or cold in nature, regulating the ascending and descending, regulating the cold and heat, tonifying spleen, eliminating dampness, promoting granulation and stopping bleeding.
Description
Technical Field
The invention relates to the field of modern Chinese medicinal preparations, in particular to a Chinese medicinal composition for preventing and treating damp-heat diarrhea and a preparation method and application thereof.
Background
The damp-heat diarrhea is characterized by diarrhea abdominal pain, urgent diarrhea, or diarrhea with difficulty, yellow and brown feces, foul smell, burning anus, burning sensation in the mouth, thirst with feverish sensation, scanty and yellow urine, red tongue with yellow and greasy coating, and slippery or soft-superficial and rapid pulse. Externally affected by the invasion of qi of damp-heat epidemic toxin and intestines and stomach, stagnation in the middle energizer, stagnation of damp-heat, qi and blood blockage, and the combination of qi and blood and damp-heat epidemic toxin into purulent blood; diarrhea due to abnormal transmission and transformation of the intestines, heat in the intestines, pathogenic heat like fire, and fire nature urgency, so diarrhea is urgent; damp-heat intermingles, so that the fu-qi is obstructed and then fails to drain; downward flow of damp-heat, burning anus, yellow-brown and smelly feces, scanty and brownish urine; extreme damp-heat in the interior can cause dysphoria with smothery sensation, thirst, yellow and greasy tongue coating, and slippery or soft-superficial and rapid pulse. The book "Jingyue quan shu" points out: when the spleen and stomach are injured due to improper diet and frequent daily life, water will be damp, food will be stagnated, essence will not be able to be transported and transformed, and even if the combined dirt will descend, diarrhea will be treated as . Although the cause of diarrhea is complex, the basic pathogenesis of diarrhea is damp excess and spleen disease, so the treatment of diarrhea should mainly clear heat and remove toxicity, invigorate spleen and resolve dampness.
The damp-heat diarrhea is similar to the clinical symptoms of colitis in western medicine, so the western medicine mostly adopts amino salicylic acid preparation, hormone or thiopurine drugs for treatment, but the treatment of the amino salicylic acid and the glucocorticoid can only control the symptoms, the curative effect is unstable, various complications are accompanied, the diarrhea is easy to relapse, and the rebound effect caused by using immunosuppressant and glucocorticoid drugs is more obvious. Therefore, the advantages of treating diarrhea due to damp-heat in western medicine are not obvious. The traditional Chinese medicine is a Chinese characteristic therapy, has self advantages in the aspect of treatment of mild and moderate damp-heat diarrhea, adopts the compatibility treatment of traditional Chinese medicines aiming at the diseases of damp-heat and diarrhea, can improve the clinical symptoms of the damp-heat diarrhea from multiple links of anti-inflammation, immunity regulation, mucous membrane repair and the like, and has the advantages of high safety, small toxic and side effects, various administration modes, reduction of complications, low price and the like. Modern pharmacological research finds that the traditional Chinese medicine achieves the purposes of relieving and treating by mainly synergistically regulating immunity and anti-inflammatory ways through multiple components. Clinically, the pathogenesis of damp-heat diarrhea is mainly 'spleen deficiency as the basis, damp-heat toxin as the target and blood stasis blocking collaterals throughout', and the treatment mainly focuses on 'tonifying qi and strengthening spleen, clearing heat and promoting diuresis, removing blood stasis and detoxifying, and promoting tissue regeneration and healing sore' as the major treatment method.
According to the symptoms of damp-heat diarrhea people, the Chinese medicinal composition is prepared by combining the characteristics of the traditional Chinese medicine clinical syndrome differentiation of the disease, and the treatment principle is to clear intestines and promote diuresis; according to the symptoms of people with spleen deficiency and diarrhea, the traditional Chinese medicine is combined with the characteristics of the traditional Chinese medicine clinical syndrome differentiation, and the treatment principle is to invigorate spleen, replenish qi, clear heat and promote the production of body fluid. The invention particularly aims at damp-heat diarrhea people, and develops and researches a safe and effective traditional Chinese medicine composition by combining animal medicines and plant medicines based on the traditional Chinese medicine theory. At present, no relevant report is found.
Disclosure of Invention
The invention aims to overcome the limitations that western medicines have single action target and strong toxic and side effects, and the existing Chinese patent medicine preparation does not systematically relieve the clinical symptoms of damp-heat diarrhea according to the basic theory of traditional Chinese medicine, and provides a traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and a preparation method and application thereof. The traditional Chinese medicine composition disclosed by the invention comprises Polyporaceae, Compositae and insect drug, wherein the Polyporaceae plant has the effects of tonifying qi and invigorating spleen, the Compositae plant has the effects of clearing away heat and toxic materials, reducing swelling and resolving masses, resisting inflammation and the like, and the insect drug has the effects of promoting blood circulation and dredging collaterals, healing sore and promoting granulation, repairing mucous membrane and the like.
In order to achieve the purpose, the invention adopts the following technical scheme:
the traditional Chinese medicine composition for preventing and treating damp-heat diarrhea is characterized by comprising the following traditional Chinese medicine raw materials in parts by weight:
10-60 parts of pesticide, 25-55 parts of compositae plants and 15-65 parts of polyporaceae plants.
Preferably, the traditional Chinese medicine raw materials comprise the following components in parts by weight:
30-35 parts of insect medicine, 35-45 parts of compositae plants and 25-30 parts of polyporaceae plants.
Most preferably, the traditional Chinese medicine raw materials comprise the following components in parts by weight:
32 parts of insect pesticide, 40 parts of compositae plants and 28 parts of polyporaceae plants.
Further, the insect drug is preferably one or a mixture of more than two of dung beetle, bee, cockroach, gadfly and dragon louse; more preferably cockroach.
Further, the Compositae plant is preferably one or more of herba Lycopi, flos Chrysanthemi, herba Artemisiae Annuae, herba Taraxaci, Atractylodis rhizoma, Burdock, Carthami flos, and herba Senecionis Scandentis;
further, the plant of Polyporaceae is preferably one or more of Polyporus, Ganoderma, Grifola frondosa, Sulfur, Poria, and Coriolus versicolor.
Further, the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight:
32 parts of cockroach, 40 parts of dandelion and 28 parts of poria cocos; or
15 parts of cockroach, 40 parts of groundsel and 45 parts of coriolus versicolor; or
29 parts of cockroach, 38 parts of sweet wormwood herb and 33 parts of sulfur bacteria; or
37 parts of cockroach, 42 parts of burdock and 21 parts of lucid ganoderma; or
23 parts of cockroach, 37 parts of bighead atractylodes rhizome and 40 parts of grifola frondosa; or
28 parts of cockroach, 40 parts of wild chrysanthemum and 32 parts of grifola; or
22 parts of cockroach, 26 parts of chrysanthemum, 20 parts of sweet wormwood herb and 32 parts of coriolus versicolor; or
27 parts of cockroach, 23 parts of chrysanthemum, 30 parts of bighead atractylodes rhizome and 20 parts of poria cocos; or
35 parts of cockroach, 30 parts of dandelion, 10 parts of safflower and 15 parts of coriolus versicolor; or
32 parts of cockroach, 20 parts of wild chrysanthemum, 20 parts of burdock and 28 parts of grifola frondosa; or
20 parts of dung beetle, 40 parts of cockroach, 20 parts of dandelion, 10 parts of grifola and 10 parts of poria cocos; or
15 parts of cockroach, 40 parts of dandelion, 25 parts of coriolus versicolor and 20 parts of grifola frondosa; or
20 parts of cockroach, 30 parts of bighead atractylodes rhizome, 30 parts of polyporus and 20 parts of coriolus versicolor; or
30 parts of cockroach, 25 parts of sweet wormwood, 20 parts of groundsel and 25 parts of lucid ganoderma; or
10 parts of cockroach, 25 parts of chrysanthemum, 30 parts of safflower and 35 parts of tuckahoe; or
32 parts of cockroach, 15 parts of wild chrysanthemum, 25 parts of dandelion and 28 parts of ganoderma lucidum; or
40 parts of cockroach, 20 parts of gadfly, 15 parts of sweet wormwood, 10 parts of safflower and 15 parts of polyporus; or
28 parts of cockroach, 10 parts of dragon louse, 21 parts of chrysanthemum, 15 parts of climbing groundsel, 16 parts of sulfur bacteria and 10 parts of coriolus versicolor; or
20 parts of dung beetle, 28 parts of cockroach, 20 parts of dragon louse, 12 parts of sweet wormwood, 10 parts of bighead atractylodes rhizome and 10 parts of poria cocos; or
14 parts of bees, 20 parts of cockroaches, 15 parts of gadflies, 15 parts of burdock, 10 parts of dandelion and 26 parts of sulfur bacteria; or
33 parts of cockroach, 16 parts of gadfly, 11 parts of safflower, 20 parts of wild chrysanthemum, 10 parts of polyporus and 10 parts of coriolus versicolor; or
20 parts of cockroach, 20 parts of gadfly, 20 parts of dragon louse, 15 parts of groundsel, 10 parts of bighead atractylodes rhizome and 15 parts of poria cocos; or
10 parts of bees, 30 parts of cockroaches, 20 parts of gadflies, 15 parts of burdock, 10 parts of safflower and 15 parts of grifola; or
10 parts of bee, 12 parts of cockroach, 10 parts of dragon louse, 25 parts of climbing groundsel herb, 15 parts of dandelion, 18 parts of grifola frondosa and 10 parts of sulfur bacteria; or
20 parts of dung beetle, 10 parts of cockroach, 10 parts of gadfly, 15 parts of sweet wormwood, 15 parts of dandelion, 13 parts of polyporus and 17 parts of coriolus versicolor.
The invention also provides a preparation method of the traditional Chinese medicine composition for preventing and treating damp-heat diarrhea, which is characterized in that the traditional Chinese medicine composition is prepared from extract of the traditional Chinese medicine raw materials and necessary auxiliary materials for preparation.
Further, the traditional Chinese medicine composition is selected from capsules, pellets, powder, tablets, granules, solutions, emulsions or suspensions; preferably, the traditional Chinese medicine composition is selected from capsules.
The invention also provides a preparation method of the traditional Chinese medicine composition for preventing and treating damp-heat diarrhea, which is characterized by comprising the following steps:
(1) taking the whole dry insect medicine, adding a proper amount of petroleum ether for extraction, degreasing, and drying at low temperature to obtain a degreased dry body of the insect medicine;
(2) weighing the dried worm medicine according to the parts by weight, and adding the dried feverfew;
(3) adding a proper amount of water into the traditional Chinese medicinal materials in the step (2), adopting a multifunctional extraction tank to set the temperature, heating and extracting, and filtering by using 400-mesh filter cloth;
(4) adding appropriate amount of water into the residue, heating for extraction, filtering, mixing filtrates, concentrating with rotary evaporator, cooling, and filtering to obtain fluid extract;
(5) collecting the fluid extract to obtain a raw material medicinal material extract;
(6) mixing the extract with powder of plant of Polyporaceae and optional filler, granulating, drying, and making into capsule.
Further, the filler is one or a combination of more than two of starch, microcrystalline cellulose, dextrin, lactose, compressible starch, mannitol and medicinal calcium carbonate.
Further, in the preparation method, preferably, the weight of the petroleum ether added in the step (1) is 1-20 times of that of the dry pesticide, and the extraction is carried out for 1-10 times, wherein the extraction time is 6-48 hours; adding water in the steps (3) and (4) in an amount which is 1-30 times of the weight of the raw medicinal materials or the filter residue, and extracting for 1-10 times for 1-5 hours; and (5) concentrating the filtrate into an extract with the density of 1.00-1.35 g/mL.
Further, in the preparation method, the weight of petroleum ether added in the step (1) is preferably 5-15 times of that of the dry pesticide, the extraction is carried out for 2-5 times, and the extraction time is 12-36 hours; adding water in the steps (3) and (4) in an amount which is 5-15 times of the weight of the raw medicinal materials or the filter residue, and extracting for 2-5 times for 1-3 hours; and (5) concentrating the filtrate into an extract with the density of 1.05-1.20 g/mL.
In a third aspect, the invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating and preventing damp-heat diarrhea symptoms.
Further, the symptoms include, but are not limited to, abdominal pain, diarrhea, mucopurulent stool, anal burning, scanty dark urine, dry mouth, and halitosis.
The traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and the preparation method and the application thereof are prepared by combining folk medicine application experience and applying modern scientific theory on the basis of the traditional theory of traditional Chinese medicine. The invention provides a damp-heat diarrhea traditional Chinese medicine formula for treating damp-heat retention in the interior of damp-heat or internal injury of diet, dysfunction of the spleen in transport and intestinal conduction, and diarrhea urgency caused by diarrhea with symptoms of abdominal pain, diarrhea, mucopurulent bloody stool, burning anus, scanty and dark urine, dry mouth and halitosis by 'supplementing qi and strengthening the spleen, clearing heat and promoting diuresis, removing blood stasis and detoxifying, promoting tissue regeneration and healing sore'. When the formula contains the insect medicament, the mucosa repair can be obviously promoted; the compound contains Compositae plants with obvious anti-inflammatory effect, and the addition of Polyporaceae plants can improve rat feces property, anal temperature, urine volume, etc. When the formula contains the insect drug, the compositae plant and the polyporaceae plant, the composition can play a role in treating damp-heat diarrhea by improving damp-heat symptoms, strengthening mucous membrane repair, regulating inflammation indexes and other pathological tissues. The monarch drug in the prescription has the functions of promoting blood circulation, dredging collaterals, healing sore and promoting granulation; the feverfew is a ministerial drug, and has the effects of clearing away heat and toxic materials, relieving swelling and resolving hard mass; the polyporaceae plant helps the monarch to tonify qi and invigorate spleen as an assistant and guide drug, promotes diuresis and excretes dampness, invigorates spleen and calms heart. The whole formula mainly aims at eliminating dampness and strengthening spleen, and takes wound healing and tissue regeneration as assistance. The three medicines are combined to achieve the effects of keeping mild or cold in nature, regulating the ascending and descending, regulating the cold and heat, tonifying spleen, eliminating dampness, promoting granulation and stopping bleeding.
Drawings
FIG. 1 is the effect of rat colon tissue (HE,. times.200).
Detailed Description
To further clarify the objects, technical solutions and advantages of the present invention, the following examples are given to illustrate the present invention, and it should be understood that the examples described herein are only for the purpose of explaining the present invention and are not intended to limit the scope of the present invention.
Example 1
A traditional Chinese medicine composition for preventing and treating damp-heat diarrhea is prepared from the following raw material medicines in parts by weight: 60 parts of cockroach and 40 parts of dandelion of Compositae.
The traditional Chinese medicine composition is a capsule, and the preparation method of the capsule comprises the following steps:
(1) taking dry insect medicine, adding petroleum ether in an amount which is 4 times that of the dry insect medicine, soaking and extracting for 3 times at room temperature, taking out the insect medicine each time for 6 hours, and drying at low temperature to obtain a degreased dry body of the insect medicine;
(2) adding the degreased and dried body of the insect drug into compositionally used Compositae plants, adding 12 times of water, extracting for 3 times by using a multifunctional extraction tank, each time for 3 hours, concentrating the filtrate to obtain an extract with the density of 1.15g/mL, cooling, filtering, and obtaining the extract for later use;
(3) adding microcrystalline cellulose and corn starch into the above extract, and making into capsule to obtain PKA.
Example 2
A traditional Chinese medicine composition for preventing and treating damp-heat diarrhea is prepared from the following raw material medicines in parts by weight: 35 parts of cockroach as an insect drug and 65 parts of polyporus umbellatus as a polyporaceae plant.
The traditional Chinese medicine composition is a capsule, and the preparation method of the capsule comprises the following steps:
(1) taking dry insect medicine, adding 6 times of petroleum ether, soaking and extracting at room temperature for 4 times, each time for 18 hours, taking out the insect medicine, and drying at low temperature to obtain degreased dry body of the insect medicine;
(2) adding 8 times of water into defatted and dried insect pesticide, extracting for 2 times with a multifunctional extraction tank for 4 hours each time, concentrating the filtrate to obtain extract with density of 1.23g/mL, cooling, and filtering to obtain extract;
(3) pulverizing Polyporaceae plant, sieving with 80 mesh sieve, adding formula amount of extract and corn starch, and making into capsule to obtain PKB.
Example 3
A traditional Chinese medicine composition for preventing and treating damp-heat diarrhea is prepared from the following raw material medicines in parts by weight: 55 parts of dandelion of Compositae and 45 parts of poria cocos of Polyporaceae.
The traditional Chinese medicine composition is a capsule, and the preparation method of the capsule comprises the following steps:
(1) weighing Compositae plant by weight, adding 5 times of water, extracting for 4 times with a multifunctional extraction tank, each time for 2 hr, concentrating the filtrate to obtain extract with density of 1.20g/mL, cooling, filtering, and collecting the extract;
(2) crushing Polyporaceae plants, sieving with 80 mesh sieve, adding formula amount of extract and microcrystalline cellulose, and making into capsule to obtain PKC.
Example 4
A traditional Chinese medicine composition for preventing and treating damp-heat diarrhea is prepared from the following raw material medicines in parts by weight: 32 parts of cockroach, 40 parts of dandelion of Compositae and 28 parts of poria cocos of Polyporaceae.
The traditional Chinese medicine composition is a capsule, and the preparation method of the capsule comprises the following steps:
(1) taking dry insect medicine, adding 10 times of petroleum ether, soaking and extracting at room temperature for 5 times, each time for 24 hours, taking out the insect medicine, and drying at low temperature to obtain degreased dry body of the insect medicine;
(2) adding the degreased and dried body of the insect drug into compositionally used Compositae plants, adding 10 times of water, extracting for 3 times by using a multifunctional extraction tank, extracting for 3 hours each time, concentrating the filtrate to obtain an extract with the density of 1.25g/mL, cooling, filtering, and obtaining the extract for later use;
(3) pulverizing Polyporaceae plant, sieving with 80 mesh sieve, adding the above extract, and making into capsule to obtain PKD.
Examples 5 to 28
The specific bulk drug formulation is shown in table 1. Extract of the Chinese medicinal material is prepared by the method of example 4, and the corresponding preparation composition is prepared by the conventional method after adding the preparation auxiliary materials necessary in the field.
TABLE 1 crude drug ratios and formulation types for examples 5-20
Taking the capsules prepared in the above examples 1-4 as examples, the basic experiments of the formula for preventing and treating damp-heat diarrhea, the preparation method and the application thereof are studied.
Test example 1
1 materials of the experiment
1.1 Experimental instruments
RT6100 enzyme-labeled analyzer (Rayto); TL-16R desk-top high speed refrigerated centrifuge (Shanghai centrifuge mechanical research institute); DHG-924OA electric hot air drying oven (Shanghai-Hengscientific instruments Co., Ltd.); METTLERAE240 precision electronic analytical balance (Mettler-Torledo instruments, Inc.); KZ-II high speed tissue milling apparatus (Wuhan Severer Biotech Co., Ltd.); DF-101S magnetic stirrer (aka instruments ltd); VORTFX-5 vortexer (Lobelir instruments manufacture, Hippon city); DXL-D rat metabolic cage (von experimental animal facilities, limited, su city); KL-UP-UV-20KNSY1059 ultrapure water machine (pure water equipment factory special for Chengdu corning experiment).
1.2 Experimental animals
SPF male SD rats 36, weight (180- & ltSUB & gt 220g), all reach the large laboratory animals company Limited, license number: SCXK (chuan) 2015-: SYXK (Dian) K2018-0002.
1.3 Experimental reagents
Chloral hydrate (national pharmaceutical group chemical agents Co., Ltd., lot number: 20170203); physiological saline (Guizhou Tiandi pharmaceutical Co., Ltd., lot No.: A15031602); laobaigan (Luzhou Lao jiao Town, Inc., lot number: GB/T22045); grease (Sanhai food trade Co., Ltd. of Changshan, Shunde district, batch number: GB 16752); dayaoyouzi honey (Dayaoyouhui food Co., Ltd., lot number: GB 14923); freund's Adjuvant, Complete (Sigma, USA, Lot: # SLBZ 9884); 2, 4, 6-trinitrobenzenesulfonic acid (Sigma, Lot:026K5006, USA); occult blood kit (Nanjing institute of bioengineering, lot number: 20190323); rat interleukin 6(IL-6) kit (batch No. ml102828), rat interleukin 8(IL-8/CXCL8) kit (batch No. ml002885), rat tumor necrosis factor alpha (TNF-alpha) kit (batch No. ml002859), rat C-reactive protein (CRP) kit (batch No. ml002999), rat transforming growth factor beta (TGF-beta) kit (batch No. ml111470), rat Myeloperoxidase (MPO) kit (batch No. ml003250), rat interleukin 2(IL-2) kit (batch No. ml102822), and rat interleukin 17(IL-17) kit (batch No. ml003003) all purchased from Shanghai enzyme-linked bioscience, Inc.
2 method of experiment
2.1 Experimental animal modelling
The preparation method of the rabbit colon antigen emulsion comprises the following steps: taking a fresh colon of a rabbit, cutting an intestinal cavity along the mesentery edge, quickly cleaning excrement by using pre-cooled physiological saline at 4 ℃, scraping colon contents, adding a proper amount of physiological saline to prepare homogenate, standing at-20 ℃ for 24h, completely thawing at 4 ℃, freezing and centrifuging at 4 ℃ for 30min at 4000rpm, continuously standing a supernatant at-20 ℃ for 24h, completely thawing at 4 ℃ for 4000rpm/min, centrifuging at 4 ℃ for 30min, observing whether precipitates exist, continuously repeating the operation if precipitates exist, freezing the supernatant at-80 ℃ after centrifugation does not exist, freeze-drying by using a freeze-drying device to prepare freeze-dried rabbit colon contents, and standing at-20 ℃ for later use. 480mg (8 mg/rabbit) of rabbit colon content freeze-dried powder is precisely weighed, 15mL of physiological saline is added to completely dissolve the rabbit colon content freeze-dried powder, 15mL of complete Freund's adjuvant is added to the rabbit colon content freeze-dried powder, and the rabbit colon content freeze-dried powder and the complete Freund's adjuvant are uniformly mixed to prepare antigen emulsion (16mg/mL) which is prepared immediately when in use.
The invention adopts a rat model of damp-heat diarrhea induced by combining high-sugar high-fat diet with alloantigen and trinitrobenzene sulfonic acid (TNBS). After a week of adaptive feeding of healthy SPF male rats, randomly selecting 6 SD rats as a normal group, feeding the SD rats according to normal diet drinking water, and feeding the model rats with high-sugar and high-fat diet on the basis of ordinary feed feeding, namely: freely drinking water by 200g/L of honey water, pouring 15g/kg of white spirit according to the weight of a rat every other day, pouring 15mL/kg of white spirit according to the dose every other day when grease is poured, alternately pouring the white spirit and the grease for 20 days in total, preparing the colon antigen emulsifier of the rabbit at the 6 th day and the 20 th day, and respectively injecting the antigen emulsifier under the left foot sole, the right foot sole, the groin and the back of the rat subcutaneously according to 0.5 mL/dose. At 21d, the rats were fasted and kept out of water for 24h, anesthetized by intraperitoneal injection using 10% chloral hydrate at a rate of 0.3mL/100g of the rat body weight, in a lying position, a polyethylene tube with a diameter of 2.0mm was gently inserted through the rat anus to a depth of about 8cm, 0.6mL of a 40% ethanol solution of 5% (w/v) trinitrobenzenesulfonic acid was slowly poured through the polyethylene tube from a 1.0mL syringe, and the rats were kept in an inverted state for 10s immediately after the polyethylene tube was pulled out. The normal group was subjected to an enema operation with 0.6mL of physiological saline. And (5) after the rat is anesthetized and revived, putting the rat back into the cage, and completing the molding.
2.2 groups of Experimental animals
After the rats are modeled, 5 days are observed, and Disease Activity Index (DAI) scores are divided into groups according to the 5 th day, wherein the scores are accumulated according to the weight condition, the stool character and the occult blood condition of the rats, the total score is 12, and the inflammation condition of the rats is divided into the following four types according to the accumulated score: very mild inflammation (0-3 points), mild inflammation (4-6 points), moderate inflammation (7-9 points), and severe inflammation (10-12 points). The present invention incorporates moderate inflammation model rats into subsequent experiments. The model rats were stratified by the degree of inflammation and then grouped by random sampling. 30 model rats were divided into 5 groups of 6 rats, model group, PKA group, PKB group, PKC group, PKD group.
2.3 administration to laboratory animals
After grouping, the gavage administration was started and continued for 14 d. The specific doses for each group were as follows: 1) normal group: normal saline was administered at a volume of 2.5 mL/kg; 2) model group: normal saline was administered at a volume of 2.5 mL/kg; 3) PKA group: administering a PKA capsule solution at a dose of 566 mg/kg; 4) PKB group: administering a PKB capsule solution at a dose of 566 mg/kg; 5) PKC group: administering a PKC capsule solution at a dose of 566 mg/kg; 6) PKD group: the PKD capsule solution was administered at a dose of 566 mg/kg.
2.4 general State Observation in rats
During the experiment, the hair, stool color and hardness, mental state, urine color, etc. of each group of rats were observed.
2.5 rat body weight
During the experiment, the hair, the excrement color and the hardness, the mental state, the urine color and the like of each group of rats are observed, the weight of the rats is recorded every day dynamically, and the change condition of the weight of the rats during the modeling and the administration is observed.
2.6 rat fecal pellet count
All rats were placed individually in clean metabolic cages at 0d, 21d, 27d, 33d, 40d, respectively, and the number of fecal particles in 12h per rat was recorded.
2.7 urine volume in rats
All rats were placed individually in clean metabolism cages at 0d, 21d, 27d, 33d, 40d, respectively, 50mL centrifuge tubes were fixed to the lower end of the metabolism cages for urine collection, and the corresponding urine volume in 12h was recorded for each rat.
2.8 anal temperature of rat
And (3) dipping a small amount of glycerine enema in 0d, 21d, 27d, 33d and 40d of the rats respectively through an electronic thermometer, slowly inserting the rats into the anus of the rats at a position of 1cm, and reading the body temperature value when the body temperature counting value is stable and an alarm sound prompts.
2.9 rat DAI score
All rats are subjected to DAI scoring on the 0d, 21d, 23d, 27d, 30d, 33d, 36d and 40d of damp heat respectively, and the disease activity condition of the rats is evaluated by calculating the disease activity index of the rats through the accumulated analysis of the body weight, the fecal character and the fecal occult blood condition of the rats according to the scoring. The scoring criteria are shown in Table 2.
TABLE 2 rat DAI score criteria
Note: normal feces is formable feces; loose stool is thin stool which is not sticky with anus; diarrhea refers to the liquid feces adhering to the anus. Weight loss (%) - (weight at a certain time point-weight before molding)/weight before molding × 100%. DAI-score for weight loss + score for stool trait + score for occult blood status.
2.10 colonic mucosal Damage index
The whole colon from about 1cm to the tail end of the cecum at the anus of a rat is taken out, redundant tissues are removed along the mesentery, the colon is flatly paved on the surface of white paper provided with a cross ruler for taking a picture, the colon is cut along the mesentery of the colon, the content in the intestinal cavity of the colon is cleaned by pre-cooled normal saline, the filter paper is precisely weighed after being wiped, the length and the width of the colon are measured by a steel ruler, the length-width ratio of the colon is calculated, the injury condition of the colon mucosa is observed by naked eyes, and the injury index of the colon mucosa is scored (Colonmucosadamage index, CMDI), wherein the scoring standard is shown in a table.
TABLE 3 Colonic Mucosal Damage Index (CMDI) score criteria
2.11 Colon pathological morphology Observation
Uniformly and longitudinally dividing colon tissues into two parts, and storing one part in a low-temperature refrigerator at the temperature of-80 ℃; the other part is processed by colon tissue routine in a mode of Swiss rolls Swiss roll, the colon tissue is longitudinally cut and wound up, and is soaked in 10% neutral formalin for 24 hours. And rinsing colon tissues, dehydrating by using alcohol, clearing dimethylbenzene, embedding paraffin, slicing by 3-5 mu m, performing HE dyeing, sealing by using neutral gum, and observing pathological sections under an optical microscope. A colon pathological morphology (HS) score was performed, referring to table 4.
TABLE 4 histopathology scoring criteria
Note: each rat colon HS score is ═ epithelial cell "score +" inflammatory cell infiltration "score.
2.12 serum cytokine assay
Collecting blood by abdominal aorta after anesthesia with chloral hydrate, standing at 4 deg.C for solidification, centrifuging at 3500rpm/min at 4 deg.C for 15min, collecting supernatant, packaging, and storing in-80 deg.C refrigerator. After subsequent gradient freeze thawing at-20 ℃ and 4 ℃, the content expression of IL-6, IL-8, TNF-alpha and CRP in the serum of the rat is detected strictly according to the operation instruction of an ELISA kit.
2.13 Colon tissue cytokine assay
Taking out the preserved colon tissue from a low-temperature refrigerator at minus 80 ℃, freezing and thawing the colon tissue at minus 20 ℃ and 4 ℃ in a gradient manner respectively, and detecting the content expression of TGF-beta, MPO, IL-2 and IL-17 in the colon of a rat by strictly related ELISA kit operation instructions.
3 results of the experiment
3.1 general status of rats
(1) Before molding: the hair of each group of rats is smooth, clean, white, lively and movable, the drinking water and urine are not abnormal, and the feces have normal texture and are dark brown and oval.
(2) During the wet-heat molding: the weight of the model-building rat rises faster firstly and slowly in the later period. The red and swollen feet, nodules in groin and back, and suppuration and rupture in a few parts appeared on the injection site of the antigen emulsion. Lassitude, loose hair, pale yellow and lusterless, drunk, lying and stacked after filling with alcohol, and less self-activity. Yellow urine, increased urine volume, occasional hematuria and burning anus. The rats in the normal group slowly gained weight, and had normal feces, body temperature and urine. The perianal filth adheres to yellow loose stools, loose and sticky stools have soft and loose texture, the stool is connected by filamentous mucus, the color is yellow and the stool has foul smell, and part of the stool has mucus, bloody stool. During TNBS induction, rats in various modeling groups are cachectic, cluttered, lazy, yellow and disordered in hair color, arched back, obviously reduced in food consumption, rapid in weight reduction, emaciation, accompanied with mucus, purulent stool, feces adhered to anus, sticky and stink, and intestinal flatulence of partial rats.
(3) During the period of drug treatment: the rats in the normal group had normal diet, slowly increased body weight and no abnormality in each physical sign. The food intake of the model group rats is improved, the mental state is recovered to a certain extent, the rats are loose in stool, blood is brought in the stool, and the weight is increased. The PKA, PKB, PBC and PKD groups have good mental state, gradually flexible reaction, greatly improved food intake, obviously increased weight, improved diarrhea, more formed excrement, less frequent and rarefaction, gradually deepened color, increased excrement amount, gradually decreased anus temperature and urine excretion amount and tend to normal rat level.
The model group rats had severe diarrhea throughout the molding period. And the body heat is not raised, the anus is scorched, the body temperature rise, tenesmus, yellow urine, yellow-brown and smelly feces and the diarrhea mucous bloody pus can be obviously sensed when the rat is touched in the experiment, and the judgment meets the evaluation standard of the damp-heat diarrhea animal model. And prompting the success of molding.
3.2 rat body weight changes
The body weight of the normal group rats slowly increased during both molding and administration. At 0d, the weights of the rats in all groups have no significant difference (P is more than 0.05), and the experimental rats are at the same normal level. During the duplication of the damp-heat model, the body weight of rats in the other groups is increased rapidly at first and slowly at later stage compared with that in the normal group, and the weight average of the rats in the model group, the PKA group, the PKB group and the PKD group is obviously increased (P is less than 0.05 or P is less than 0.01) at the 21 st day of damp-heat. During observation period after TNBS modeling, except for normal group, the weight average of rats in other groups is reduced, and during drug treatment period, the weight of PKB and PKD is increased rapidly, and the weight of rats in model group is increased slowly. The results are shown in Table 5.
TABLE 5 Effect of rat body weight: (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; compared to the model group, Δ P < 0.05.
3.3 Effect of rat fecal particle count
The damp-heat is 0d, the number of the defecation particles of the rats in each group has no significant difference (P is more than 0.05), and the experimental rats are at the same normal level. On the 21 st day of damp-heat, the number of fecal particles was significantly increased in the model, PKA, PKB, PKC and PKD groups compared to the normal group (P <0.05 or P < 0.01), suggesting that factors responsible for damp-heat may disturb fecal excretion in rats. At 40d, drug treatment was terminated, and the number of fecal particles was reduced in the PKC and PKD groups compared to the model group (P < 0.05), suggesting that the capsule formulation formulated with Polyporaceae plants could improve the damp-heat syndrome of the rat fecal count, with the results shown in Table 6.
TABLE 6 Effect of the number of faecal particles at different time points in the rats: (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; compared to the model group, Δ P < 0.05.
3.4 Effect of urine volume in rats
The damp-heat is 0d, the urine volume of each group of rats has no significant difference (P is more than 0.05), and the experimental rats are at the same normal level. At 21d, the urine volume of the rats in the other groups was increased compared to the normal group, indicating that the endogenous factors of damp-heat may cause the urine excretion of the rats to increase. At 27d, urine volume was significantly increased (P < 0.05) in the remaining rats compared to the normal group. At the 40 th day, the treatment is finished, and compared with the normal group, the urine volume of the model group is still obviously increased (P is less than 0.05); compared with the model group, the urine volume of the PKB and PKD groups is obviously reduced (P is less than 0.05), and is closer to that of the normal group. The capsule formulation formulated with the Polyporaceae plant was suggested to improve damp-heat syndrome in the volume of rat urine, and the results are shown in Table 7.
Table 7 effect of urine volume in rats: (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; compared to the model group, Δ P < 0.05.
3.5 Effect of rat anal temperature
The damp-heat is 0d, and the anal temperature of rats in each group has no significant difference (P is more than 0.05). In the 21 st day of damp-heat treatment, compared with the normal group, the anal temperature of rats in other groups is obviously increased (P is less than 0.01), which indicates that the damp-heat symptoms of rats are caused by high sugar, high fat, spicy diet and the like. At 40d, the drug treatment is finished, and the anal temperature of the PKB and PKD groups is closer to that of the normal group. The capsule formulation formulated with the Polyporaceae plant is suggested to improve damp-heat syndrome of rat anal temperature, and the results are shown in Table 8.
TABLE 8 influence of anal temperature in DHD rats: (
n＝6)
Note: p <0.05, P <0.01 compared to normal group.
3.6 Effect of rat DAI score
Damp-heat 0d, no significant difference in DAI scores among the groups of rats (P > 0.05) indicated that all experimental rats were at the same normal level. On the 21 st day of damp-heat, the DAI score of rats in the other groups is obviously increased (P is less than 0.05 or P is less than 0.01) compared with that of the normal group, which indicates that the damp-heat factor aggravates diarrhea of rats. 23d, compared with the normal group, the DAI scores of the rats in the other groups are obviously increased (P is less than 0.01), and the DAI scores of the rats in the other groups have no obvious difference, so that the rats in the damp-heat diarrhea model are successfully copied. 40d, after the treatment period of the drugs for two weeks, compared with the normal group, the DAI scores of the model group and each drug treatment group are obviously increased (P is less than 0.01); compared with the model group, the DAI scores of the PKB and PKD groups are both reduced remarkably (P < 0.01). It is suggested that the capsule formulation formulated with Polyporaceae plants can reduce rat DAI score by reducing damp-heat symptoms such as fecal characteristics and occult blood conditions, and the results are shown in Table 9.
TABLE 9 influence of DHD rat fecal DAI score (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; compared with the model group, the delta P is less than 0.05, and the delta P is less than 0.01.
3.7 Effect of colonic mucosal Damage index CMDI
By observing the state comparison of the longitudinal dissection intestinal wall of the colon of each group of rats by naked eyes, the colon of the normal group of rats is longer, the surface of the colon mucous membrane is smooth, and no obvious hyperemia edema, erosion or ulcer formation phenomenon is found, the length of the colon of the model group of rats is obviously shortened, the width of the colon of the model group of rats is obviously widened, hyperemia edema, erosion and ulcer with different degrees appear on the surface of the colon mucous membrane, and partial rats have surface necrosis, inflammatory polyp or toxic megacolon phenomenon. The pathological changes of the colon mucous membrane of rats in PKA, PKB, PKC and PKD groups are improved in different degrees compared with the pathological changes of model groups, the hyperemia and edema phenomenon is reduced or disappeared, and the ulcer points and the ulcer areas are reduced or disappeared. Compared with the normal group, the length and the width of the colon of the rat in the model group are both obviously reduced (P < 0.01), and the CMDI score is both obviously increased (P < 0.01). Compared with the model group, the PKA and PKD groups showed an increase in colon length (P < 0.05), a decrease in colon width and a decrease in CMDI score (P < 0.01). The results are shown in Table 10.
TABLE 10 influence of colon-related indices in rats (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; compared with the model group, the delta P is less than 0.05, and the delta P is less than 0.01.
3.8 Effect of Colon histopathology HS score
The pathological condition of the colon of each group of rats is observed through colon histopathological sections, the colon mucous membrane of the rat in the normal group has complete structure, normal cell form, continuous mucous membrane epithelium and regular gland arrangement, the crypt form is normal, a small amount of goblet cells are lost, and a small amount of inflammatory cells are infiltrated in the crypt basal layer. The colon mucosa of the rat in the model group is thickened, the mucosa muscle is edematous, the lamina propria is bleeding, the goblet cells are lost in a large area, the crypt is damaged in different degrees, and a large amount of neutrophils infiltrate into the mucosa layer and the submucosa. The pathological changes of rat colon mucous membrane in PKA, PKB, PKC and PKD groups are improved to different degrees compared with model groups, partial goblet cells are repaired, and inflammatory cell infiltration area is reduced. Compared with the normal group, the epithelial cell score, inflammatory cell infiltration score and HS score of the model group rats and the drug treatment groups are obviously increased (P is less than 0.05 or P is less than 0.01). Compared to the model group, PKA, PKB and PKD rats had decreased colonic epithelial cell score, inflammatory cell infiltration score and HS score (P <0.05 or P < 0.01). The results are shown in Table 11 and FIG. 1.
TABLE 11 Effect of rat Colon histopathology scores (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; Δ P <0.01 compared to the model group.
3.9 Effect of rat serum cytokines
Compared with the normal group, the serum IL-6, IL-8, TNF-alpha and CRP of the model group rats are obviously increased (P is less than 0.01). Compared with the model group, the mouse serum IL-6, IL-8, TNF-alpha and CRP expression levels of PKA and PKD groups are all obviously reduced (P < 0.01), and the mouse serum TNF-alpha and CRP expression levels of PKC group are reduced on average (P < 0.05). The experimental result shows that the formula containing the compositae plants can effectively reduce the expression of inflammatory factors, and the anti-inflammatory effect is most obvious when the formula contains the insect medicament, the compositae plants and the polyporaceae plants simultaneously. The results are shown in Table 12.
TABLE 12 Effect of rat serum cytokines: (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; compared with the model group, the delta P is less than 0.05, and the delta P is less than 0.01.
3.10 Effect of rat Colon tissue cytokines
Compared with the normal group, the rat colon MPO, IL-2 and IL-17 expression level of the model group is obviously increased on average (P < 0.01), and the TGF-beta expression level is obviously reduced (P < 0.01). Compared with the model group, the colon IL-2 and IL-17 expression level of rats in PKA, PKB and PKD groups is reduced on average (P < 0.01) and the expression level of TGF-beta is increased on average (P < 0.01). The mean level of MPO expression was significantly reduced in the colon for rats in PKA, PKC and PKD groups (P < 0.01). The experiment results show that when the composition contains compositae plants, MPO inflammatory factor expression can be effectively reduced, and when the composition contains insect drugs, the mucous membrane repair indexes can be repaired, and when the composition contains the insect drugs, the compositae plants and polyporaceae plants, the anti-inflammatory effect and the mucous membrane repair degree are most obvious. The results are shown in Table 13.
TABLE 13 Effect of rat Colon tissue cytokines: (
n＝6)
Note: p <0.05, P <0.01 compared to normal group; compared with the model group, the delta P is less than 0.05, and the delta P is less than 0.01.
The disease is manifested by diarrhea, mucopurulent bloody stool, burning anus, sticky stool, dysphoria with smothery sensation, thirst, scanty and brownish urine, red tongue, yellow and greasy tongue coating, soft and rapid pulse, erosion and ulcer of the mucous membrane of colon, massive inflammatory cell infiltration, abscess of crypt, etc. which are typical symptoms of damp-heat in colonoscopy. The experimental result shows that the anus of the rat in the model group is scorched, the rat is heavy after tenesmus, the urine is yellow, the feces are yellow brown and smelly, the diarrhea mucous, purulent stool, lassitude, the dorsum of the arch, loose hair color, pale yellow and lusterless, the rat is drunk after being drunk, lying and piling up, the autonomous activity is less, and the successful replication of the DHD animal model is prompted. When the formula contains the insect medicament, the mucous membrane repair can be obviously promoted, when the formula contains the compositae plants, the anti-inflammatory effect is obvious, and the damp-heat indexes such as the stool character, the anal temperature, the urine volume and the like of a rat can be obviously improved by adding the polyporaceae plants in the formula. The composition is indicated to have the effect of treating damp-heat diarrhea by improving damp-heat symptoms, strengthening mucous membrane repair, regulating inflammation indexes and other pathological tissues when the composition simultaneously contains the insect medicament, the compositae plants and the polyporaceae plants.
The intestinal mucosa barrier is used for inhibiting harmful substances in intestines from penetrating through the intestinal mucosa through intestinal mucus and immune-related cells, resisting the invasion of endogenous or exogenous antigens, and maintaining the stability of the internal environment of an organism, and is mainly related to normal regulation and control of intestinal secretion, intestinal mucosa epithelial cells, an intestinal immune system and the like. The abnormal barrier function can cause various cell activation and secretion of various inflammatory mediators through nonspecific inflammatory reaction to cause imbalance of intestinal tract homeostasis, and the intestinal mucosa barrier can not continuously maintain homeostasis, so that the intestinal mucosa tissue is damaged, and the abnormal barrier function plays a vital role in the pathogenesis of damp-heat diarrhea. Cytokines are small molecular polypeptides or proteins which are produced by cells and have various biological functions, and play roles in mediating inflammation and regulating immunity in immune response of a body. Among them, the UC-related cytokines can be classified into two categories, i.e., proinflammatory factors and anti-inflammatory factors, such as Interferon (IFN), Interleukin (IL), Tumor Necrosis Factor (TNF), etc., according to their action characteristics. And the intestinal mucosa can be damaged by inflammatory reaction and immune disorder caused by the imbalance of proinflammatory factors and inflammation inhibiting factors in the body. The experimental result shows that the expression levels of IL-6, IL-8, TNF-alpha, CRP and colon tissue MPO, IL-2 and IL-17 in the rat serum of the model group are obviously increased compared with the normal group, and the expression of TGF-beta is obviously reduced (P is less than 0.01).
The foregoing is a more detailed description of the invention, taken in conjunction with specific preferred embodiments, and it is not intended that the invention be limited to the specific details set forth herein. It will be understood by those skilled in the art that various alternatives and modifications may be made to the described embodiments without departing from the spirit of the invention and these alternatives and modifications are to be considered as within the scope of the invention.
Claims (10)
1. The traditional Chinese medicine composition for preventing and treating damp-heat diarrhea is characterized by comprising the following traditional Chinese medicine raw materials in parts by weight:
10-60 parts of pesticide, 25-55 parts of compositae plants and 15-65 parts of polyporaceae plants.
2. The traditional Chinese medicine composition as claimed in claim 1, wherein the traditional Chinese medicine raw materials comprise the following components in parts by weight:
30-35 parts of insect medicine, 35-45 parts of compositae plants and 25-30 parts of polyporaceae plants.
3. The Chinese medicinal composition according to claim 1, wherein the insect drug is preferably selected from dung beetle, bee, cockroach, Tabanus, and Lobster; more preferably cockroaches;
the Compositae plant is preferably one or more of flos Chrysanthemi Indici, flos Chrysanthemi, herba Artemisiae Annuae, herba Taraxaci, Atractylodis rhizoma, Burdock, Carthami flos, and herba Senecionis Scandentis;
the plant of Polyporaceae is preferably one or more of Polyporus, Ganoderma, Grifola frondosa, Sulfur bacteria, Poria, and Coriolus versicolor.
4. The traditional Chinese medicine composition as claimed in claim 1, wherein the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight:
32 parts of cockroach, 40 parts of dandelion and 28 parts of poria cocos; or
15 parts of cockroach, 40 parts of groundsel and 45 parts of coriolus versicolor; or
29 parts of cockroach, 38 parts of sweet wormwood herb and 33 parts of sulfur bacteria; or
37 parts of cockroach, 42 parts of burdock and 21 parts of lucid ganoderma; or
23 parts of cockroach, 37 parts of bighead atractylodes rhizome and 40 parts of grifola frondosa; or
28 parts of cockroach, 40 parts of wild chrysanthemum and 32 parts of grifola; or
22 parts of cockroach, 26 parts of chrysanthemum, 20 parts of sweet wormwood herb and 32 parts of coriolus versicolor; or
27 parts of cockroach, 23 parts of chrysanthemum, 30 parts of bighead atractylodes rhizome and 20 parts of poria cocos; or
35 parts of cockroach, 30 parts of dandelion, 10 parts of safflower and 15 parts of coriolus versicolor; or
32 parts of cockroach, 20 parts of wild chrysanthemum, 20 parts of burdock and 28 parts of grifola frondosa; or
20 parts of dung beetle, 40 parts of cockroach, 20 parts of dandelion, 10 parts of grifola and 10 parts of poria cocos; or
15 parts of cockroach, 40 parts of dandelion, 25 parts of coriolus versicolor and 20 parts of grifola frondosa; or
20 parts of cockroach, 30 parts of bighead atractylodes rhizome, 30 parts of polyporus and 20 parts of coriolus versicolor; or
30 parts of cockroach, 25 parts of sweet wormwood, 20 parts of groundsel and 25 parts of lucid ganoderma; or
10 parts of cockroach, 25 parts of chrysanthemum, 30 parts of safflower and 35 parts of tuckahoe; or
32 parts of cockroach, 15 parts of wild chrysanthemum, 25 parts of dandelion and 28 parts of ganoderma lucidum; or
40 parts of cockroach, 20 parts of gadfly, 15 parts of sweet wormwood, 10 parts of safflower and 15 parts of polyporus; or
28 parts of cockroach, 10 parts of dragon louse, 21 parts of chrysanthemum, 15 parts of climbing groundsel, 16 parts of sulfur bacteria and 10 parts of coriolus versicolor; or
20 parts of dung beetle, 28 parts of cockroach, 20 parts of dragon louse, 12 parts of sweet wormwood, 10 parts of bighead atractylodes rhizome and 10 parts of poria cocos; or
14 parts of bees, 20 parts of cockroaches, 15 parts of gadflies, 15 parts of burdock, 10 parts of dandelion and 26 parts of sulfur bacteria; or
33 parts of cockroach, 16 parts of gadfly, 11 parts of safflower, 20 parts of wild chrysanthemum, 10 parts of polyporus and 10 parts of coriolus versicolor; or
20 parts of cockroach, 20 parts of gadfly, 20 parts of dragon louse, 15 parts of groundsel, 10 parts of bighead atractylodes rhizome and 15 parts of poria cocos; or
10 parts of bees, 30 parts of cockroaches, 20 parts of gadflies, 15 parts of burdock, 10 parts of safflower and 15 parts of grifola; or
10 parts of bee, 12 parts of cockroach, 10 parts of dragon louse, 25 parts of climbing groundsel herb, 15 parts of dandelion, 18 parts of grifola frondosa and 10 parts of sulfur bacteria; or
20 parts of dung beetle, 10 parts of cockroach, 10 parts of gadfly, 15 parts of sweet wormwood, 15 parts of dandelion, 13 parts of polyporus and 17 parts of coriolus versicolor.
5. The method for preparing a Chinese medicinal composition according to any one of claims 1 to 4, wherein the Chinese medicinal composition is prepared from extract of the Chinese medicinal materials and necessary pharmaceutical excipients; the traditional Chinese medicine composition is selected from capsules, pellets, powder, tablets, granules, solutions, emulsions or suspensions; preferably, the traditional Chinese medicine composition is selected from capsules.
6. The method of claim 5, comprising the steps of:
(1) taking the whole dry insect medicine, adding a proper amount of petroleum ether for extraction, degreasing, and drying at low temperature to obtain a degreased dry body of the insect medicine;
(2) weighing the dried worm medicine according to the parts by weight, and adding the dried feverfew;
(3) adding a proper amount of water into the traditional Chinese medicinal materials in the step (2), adopting a multifunctional extraction tank to set the temperature, heating and extracting, and filtering by using 400-mesh filter cloth;
(4) adding appropriate amount of water into the residue, heating for extraction, filtering, mixing filtrates, concentrating with rotary evaporator, cooling, and filtering to obtain fluid extract;
(5) collecting the fluid extract to obtain a raw material medicinal material extract;
(6) mixing the extract with powder of plant of Polyporaceae and optional filler, granulating, drying, and making into capsule.
7. The method according to claim 6, wherein the filler is one or a combination of two or more of starch, microcrystalline cellulose, dextrin, lactose, compressible starch, mannitol, and medicinal calcium carbonate.
8. The preparation method according to claim 6, wherein in the preparation method, preferably, the weight of the petroleum ether added in the step (1) is 1-20 times of that of the dry pesticide, and the extraction is performed for 1-10 times, wherein the extraction time is 6-48 hours; adding water in the steps (3) and (4) in an amount which is 1-30 times of the weight of the raw medicinal materials or the filter residue, and extracting for 1-10 times for 1-5 hours; concentrating the filtrate in the step (5) to obtain an extract with the density of 1.00-1.35 g/mL;
preferably, the weight of the petroleum ether added in the step (1) is 5-15 times of that of the dry pesticide, and the extraction is carried out for 2-5 times, wherein the extraction time is 12-36 hours; adding water in the steps (3) and (4) in an amount which is 5-15 times of the weight of the raw medicinal materials or the filter residue, and extracting for 2-5 times for 1-3 hours; and (5) concentrating the filtrate into an extract with the density of 1.05-1.20 g/mL.
9. Use of a Chinese medicinal composition according to any one of claims 1-4 in the preparation of a medicament for the treatment and prevention of the symptoms of damp-heat diarrhea.
10. The use of claim 9, wherein the symptoms include, but are not limited to, abdominal pain, diarrhea, mucopurulent stool, anal burning, scanty dark urine, dry mouth, and halitosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010842875.1A CN111803648B (en) | 2020-08-20 | 2020-08-20 | Traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010842875.1A CN111803648B (en) | 2020-08-20 | 2020-08-20 | Traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111803648A true CN111803648A (en) | 2020-10-23 |
| CN111803648B CN111803648B (en) | 2022-05-10 |
Family
ID=72860443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010842875.1A Active CN111803648B (en) | 2020-08-20 | 2020-08-20 | Traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111803648B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228551A (en) * | 2011-06-30 | 2011-11-02 | 王智森 | Chinese medicinal composition for preventing and treating injury of gastric mucosa and preparation method thereof |
| CN102885857A (en) * | 2012-11-10 | 2013-01-23 | 昆明赛诺制药有限公司 | Extraction method of periplaneta americana extract for treating peptic ulcer |
| CN103285106A (en) * | 2012-02-27 | 2013-09-11 | 上海中医药大学附属曙光医院 | Traditional Chinese medicinal composition for treating intestinal mucosa damage and preparation method and application thereof |
| CN104324291A (en) * | 2014-11-17 | 2015-02-04 | 青岛恒波仪器有限公司 | Traditional Chinese medicine preparation for treating large intestine damp-heat type hemafecia and preparation method of traditional Chinese medicine preparation |
| CN107753538A (en) * | 2016-12-01 | 2018-03-06 | 四川好医生攀西药业有限责任公司 | The composition of a kind of blattaria and pseudo-ginseng and its application |
| CN108283668A (en) * | 2018-02-13 | 2018-07-17 | 云南诺漫斯生物科技有限公司 | A kind of gastric ulcer composition of American-cockroach-extract-containing and preparation method thereof |
-
2020
- 2020-08-20 CN CN202010842875.1A patent/CN111803648B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228551A (en) * | 2011-06-30 | 2011-11-02 | 王智森 | Chinese medicinal composition for preventing and treating injury of gastric mucosa and preparation method thereof |
| CN103285106A (en) * | 2012-02-27 | 2013-09-11 | 上海中医药大学附属曙光医院 | Traditional Chinese medicinal composition for treating intestinal mucosa damage and preparation method and application thereof |
| CN102885857A (en) * | 2012-11-10 | 2013-01-23 | 昆明赛诺制药有限公司 | Extraction method of periplaneta americana extract for treating peptic ulcer |
| CN104324291A (en) * | 2014-11-17 | 2015-02-04 | 青岛恒波仪器有限公司 | Traditional Chinese medicine preparation for treating large intestine damp-heat type hemafecia and preparation method of traditional Chinese medicine preparation |
| CN107753538A (en) * | 2016-12-01 | 2018-03-06 | 四川好医生攀西药业有限责任公司 | The composition of a kind of blattaria and pseudo-ginseng and its application |
| CN108283668A (en) * | 2018-02-13 | 2018-07-17 | 云南诺漫斯生物科技有限公司 | A kind of gastric ulcer composition of American-cockroach-extract-containing and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 满红霞: "药用昆虫美洲大蠊化学成分及其药理作用的研究进展", 《抗感染药学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111803648B (en) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bezerra et al. | Latex proteins from Calotropis procera: toxicity and immunological tolerance revisited | |
| CA3219768A1 (en) | Pharmaceutical composition for treating rheumatoid arthritis and preparation method therefor | |
| CN112641921B (en) | Cockroach polypeptide effective part for treating ulcerative colitis and preparation method and application thereof | |
| CN111803648B (en) | Traditional Chinese medicine composition for preventing and treating damp-heat diarrhea and preparation method and application thereof | |
| CN113940945A (en) | Application of houttuynia polysaccharide in preparation of medicine for preventing and treating inflammatory bowel disease | |
| CN114869928B (en) | Traditional Chinese medicine composition for treating cerebrovascular diseases and application thereof | |
| CN114796283B (en) | Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition | |
| CN107320659B (en) | A Chinese medicinal composition for treating ulcerative colitis and preparation method thereof | |
| CN1326535C (en) | Medicine for treating bong arthritis and its preparing method | |
| CN107875211B (en) | Composition for treating ulcerative colitis and preparation method and application thereof | |
| CN105497167A (en) | New application of radix ranunculi ternati in preparation of medicine for treating and/or preventing ulcerative colitis | |
| CN108969513B (en) | Establishment and application of liver depression and spleen deficiency type ulcerative colitis animal model | |
| CN113908149A (en) | Application of formononetin in preparation of medicine for preventing and treating acute lung injury | |
| CN113197909A (en) | Application of peimine in preparation of medicine for preventing and/or treating ulcerative colitis | |
| CN113069481A (en) | Application of echinacea purpurea extract in preparation of drugs for preventing and/or treating damp-heat diarrhea | |
| CN114073720B (en) | Compound traditional Chinese medicine for treating damp-heat type ulcerative colitis and preparation method and application thereof | |
| CN107485655B (en) | Application of peach blossom extract in preparation of medicine for treating prostatitis | |
| CN1241596C (en) | Oral Chinese traditional medicine preparation for treating cystitis | |
| CN116236513B (en) | Application of artemisia sphaerocephala root extract in preparation of anti-rheumatoid arthritis drugs | |
| CN104042879A (en) | Traditional Chinese medicine granules for reversing precancerous lesions of chronic atrophic gastritis and preparation method thereof | |
| CN106692862A (en) | Application of fructus amomi volatile oil in preparing medicine for treating Crohn disease | |
| CN108354920B (en) | Application of sulfoxide compound in treating inflammatory bowel disease | |
| CN113796542B (en) | Application of sea cucumber vitellin in preparation of functional food for relieving colonitis | |
| CN108703962A (en) | Purposes of the linalool compound in preparing antirheumatic | |
| CN111759978B (en) | Traditional Chinese medicine composition for treating ulcerative colitis and eczema as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |